Shiladitya Sengupta

Dr. Shiladitya Sengupta


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
TSTanmoy Saha
Tanmoy Saha
CDChinmayee Dash
Chinmayee Dash
RJRuparoshni Jayabalan
Ruparoshni Jayabalan
SKSachin Khiste
Sachin Khiste
AKArpita Kulkarni
Arpita Kulkarni
SSShiladitya Sengupta
Shiladitya Sengupta

11 February 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAaron Goldman
Aaron Goldman
BMBiswanath Majumder
Biswanath Majumder
ADAndrew Dhawan
Andrew Dhawan
SRSudharshan Ravi
Sudharshan Ravi
DGDavid Goldman
David Goldman
SSShiladitya Sengupta
Shiladitya Sengupta
Understanding the emerging models of adaptive resistance is key to overcoming cancer chemotherapy failure. Using human breast cancer explants, in vitro cell lines, mouse in vivo studies and mathematical modelling, here we show that exposure to a taxane induces phenotypic cell state transition towards a favoured transient CD44HiCD24Hi chemotherapy-tolerant state. This state is associated with a clustering of CD44 and CD24 in membrane lipid rafts, leading to the activation of Src Family Kinase (SFK)/hemopoietic cell kinase (Hck) and suppression of apoptosis. The use of pharmacological inhibitors of SFK/Hck in combination with taxanes in a temporally constrained manner, where the kinase inhibitor is administered post taxane treatment, but not when co-administered, markedly sensitizes the chemotolerant cells to the chemotherapy. This approach of harnessing chemotherapy-induced phenotypic cell state transition for improving antitumour outcome could emerge as a translational strategy for the management of cancer.

13 September 2024 in Cell
Verified
Journal Article
Open access
JBJeremy G. Baldwin
Jeremy G. Baldwin
CHChristoph Heuser-Loy
Christoph Heuser-Loy
TSTanmoy Saha
Tanmoy Saha
RSRoland C. Schelker
Roland C. Schelker
DSDragana Slavkovic-Lukic
Dragana Slavkovic-Lukic
LGLuca Gattinoni
Luca Gattinoni
Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8+ T cells. Optimal mitochondrial transfer required Talin 2 on both donor and recipient cells. CD8+ T cells with donated mitochondria displayed enhanced mitochondrial respiration and spare respiratory capacity. When transferred into tumor-bearing hosts, these supercharged T cells expanded more robustly, infiltrated the tumor more efficiently, and exhibited fewer signs of exhaustion compared with T cells that did not take up mitochondria. As a result, mitochondria-boosted CD8+ T cells mediated superior antitumor responses, prolonging animal survival. These findings establish intercellular mitochondrial transfer as a prototype of organelle medicine, opening avenues to next-generation cell therapies.

7 September 2004 in Circulation
Verified
Journal Article
Closed access
SSShiladitya Sengupta
Shiladitya Sengupta
STSue-Anne Toh
Sue-Anne Toh
LSLynda A. Sellers
Lynda A. Sellers
JSJeremy N. Skepper
Jeremy N. Skepper
PKPieter Koolwijk
Pieter Koolwijk
TFTai-Ping D. Fan
Tai-Ping D. Fan
Background— Ginseng is a commonly used nutraceutical. Intriguingly, existing literature reports both wound-healing and antitumor effects of ginseng extract through opposing activities on the vascular system. To elucidate this perplexity, we merged a chemical fingerprinting approach with a deconstructional study of the effects of pure molecules from ginseng extract on angiogenesis. Methods and Results— A mass spectrometric compositional analysis of American, Chinese and Korean, and Sanqi ginseng revealed distinct “sterol ginsenoside” fingerprints, especially in the ratio between a triol, Rg1, and a diol, Rb1, the 2 most prevalent constituents. Using a Matrigel implant model and reconstituting the extracts using distinct ratios of the 2 ginsenosides, we demonstrate that the dominance of Rg1 leads to angiogenesis, whereas Rb1 exerts an opposing effect. Rg1 also promoted functional neovascularization into a polymer scaffold in vivo and the proliferation of, chemoinvasion of, and tubulogenesis by endothelial cells in vitro, an effect mediated through the expression of nitric oxide synthase and the phosphatidylinositol-3 kinase→Akt pathway. In contrast, Rb1 inhibited the earliest step in angiogenesis, the chemoinvasion of endothelial cells. Conclusions— The present study explains, for the first time, the ambiguity about the effects of ginseng in vascular pathophysiology based on the existence of opposing active principles in the extract. We also unraveled a speciogeographic variation impinging on the compositional fingerprint that may modulate the final phenotype. This emphasizes the need for regulations standardizing herbal therapy, currently under the Dietary Supplement and Health Education Act. Furthermore, we propose that Rg1 could be a prototype for a novel group of nonpeptide molecules that can induce therapeutic angiogenesis, such as in wound healing.

14 August 2009 in ACS Nano
Verified
Journal Article
Closed access
PCPadmaparna Chaudhuri
Padmaparna Chaudhuri
APAbhimanyu Paraskar
Abhimanyu Paraskar
SSShivani Soni
Shivani Soni
RMRaghunath A. Mashelkar
Raghunath A. Mashelkar
SSShiladitya Sengupta
Shiladitya Sengupta

2 July 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AKAshish Kulkarni
Ashish Kulkarni
VCVineethkrishna Chandrasekar
Vineethkrishna Chandrasekar
SNSiva Kumar Natarajan
Siva Kumar Natarajan
ARAnujan Ramesh
Anujan Ramesh
PPPrithvi Pandey
Prithvi Pandey
SSShiladitya Sengupta
Shiladitya Sengupta